Choose which categories of cookies you allow. Strictly necessary cookies are always on.
Required for core site functionality, security and your session. Always active.
Help us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
Used to measure campaigns and show you relevant ads on other sites (e.g. LinkedIn, Google Ads).
| Item | Description |
| CompanyName | Johnson and Johnson |
| Website | www.jnj.com |
| Established Date | 1886 |
| Headquartered | United States |
| Market Position or History | DePuy was acquired by Johnson & Johnson in 1998, rolling it into the Medical Devices group. Johnson & Johnson acquired George F. Merson's company in 1947, and it was renamed Ethicon Suture Laboratories. In 1953 this became Ethicon Inc. In July 2017, Johnson & Johnson Vision Care, Inc announced that its Abbott Medical Optics subsidiary would acquire TearScience. In August 2020, it was announced that Johnson & Johnson is set to buy the biotech company Momenta Pharmaceuticals. |
| Sales Area | World wide |
| Contact Information |
Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, US. Tel: 1-800-950-5089 |
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields.
| Product | Product Description |
| BAERVELDT | BAERVELDT Implants only require single-quadrant insertion, allowing for better IOP control than competing implants. The BAERVELDT Implants’ patented bleb control mechanism allows fibrotic tissue growth through the fenestrations in the plate, controlling bleb height and volume. |
Need a tailored company profile or competitive intelligence report? Our analysts are ready to help.
Contact Our ExpertsExplore all published company profiles across 30+ industry verticals.
View All Profiles